Glenmark Pharmaceuticals acquires certain OTC drugs from Wockhardt in US
Glenmark said its current portfolio consists of 175 products authorised for distribution in the US market and 48 ANDAs pending approval with the USFDA28-06-2022
28-06-2022
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals Inc., USA continues to expand its Over-The-Counter (OTC) Portfolio with the acquisition of approved ANDAs from Wockhardt Limited28-06-2022
GLENMARK PHARMACEUTICALS LTD. - 532296 - U.S. FDA Inspection At The Company''s Baddi, India Facility
U.S. FDA inspection at the Company''s Baddi, India Facility22-06-2022
Glenmark Pharma launches asthma drug Indamet
The Mumbai-based drug major has launched - Indacaterol Mometasone FDC under the brand name Indamet.16-06-2022
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark becomes the First Pharmaceutical Company to launch Indacaterol + Mometasone Fixed-Dose Combination Drug for Asthma in India16-06-2022
Glenmark Pharma shares hit 52-week low on reports of USFDA inspection at Baddi plant
Company's consolidated profit after tax declined 26 percent to Rs 173 crore for the fourth quarter ended March 31, 2022.13-06-2022
GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure Of Related Party Transactions For The Half Year Ended 31St March, 2022
Disclosure of Related Party Transactions for the half year ended 31st March, 202210-06-2022
GLENMARK PHARMACEUTICALS LTD. - 532296 - Minutes Of The Resolutions Passed By Way Of Postal Ballot Through Remote E-Voting Process
Minutes of the Resolution passed by way of Postal Ballot through remote e-voting process09-06-2022
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Further to our letter dated 19th May, 2022 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the transcript of the Earnings call held on Monday, May 30, 2022 for the quarter and year ended March 31, 2022 has been uploaded on the Company's website.03-06-2022
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Q4 & FY22 Earnings Call30-05-2022